Show/Hide Menu


MOR208 is a humanized monoclonal antibody that targets the antigen CD19 for the treatment of B cell malignancies.

B cell malignancies, such as non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL) afflict 150,000 people in the seven major markets each year.

MOR208 is a monoclonal antibody directed against the antigen CD19 which is broadly expressed in B-cell malignancies, such as non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL).


MOR208 has been engineered to possess significantly enhanced antibody-dependent cell-mediated cytotoxicity (ADCC), thus improving a key mechanism for tumor cell killing and offering potential for enhanced efficacy compared to traditional antibodies for the treatment of cancer.

MorphoSys presented in 2015 positiv phase 2 clinical data in patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL). In 2016, MorphoSys announced the start of a first clinical combination trial called L-MIND (Lenalidomide-MOR208 IN DLBCL). This study is designed to evaluate the safety and efficacy of MOR208 in combination with the immunomodulatory drug lenalidomide in patients with diffuse large B cell lymphoma (DLBCL). The trial is designed as an open-label, single-arm study, with the primary endpoint being the overall response rate (ORR) and multiple secondary endpoints, including progression-free survival (PFS), overall survival (OS) and time to progression (TTP).


Another ongoing, investigator-initiated trial phase 2 study, initiated by the Ohio State University, the combination of MOR208 and lenalidomid is being evaluated in relapsed/refractory and treatment-naive chronic lymphocytic leukemia (CLL) patients.

The MOR208 target (CD19) is expressed more broadly and earlier in B cell development than CD20, the target of the marketed cancer drug rituximab, therefore potentially allowing for an even broader use of MOR208 as compared to rituximab.

In June 2010, MorphoSys AG and the Xencor, Inc. signed a worldwide exclusive license agreement for the antibody. The agreement provided MorphoSys with an exclusive worldwide license to XmAb5574, which was subsequently renamed MOR208.

MOR208 was granted orphan drug designation in DLBCL (US and Europa) and CLL (US and Europe). Additionally, the FDA has granted fast track designation for the treatment of DLBCL.

Poster MOR208 subgroup analysis in NHL presented at the 2016 ASCO Annual Meeting
(PDF, 364 KB)
Poster planed combination trial MOR208 in CLL & SLL presented at the 2016 ASCO Annual Meeting
(PDF, 1 MB)
Oral presentation referring to MOR208 subgroup analysis, held at EHA 2016 by Dr. Wojciech Jurczak
(PDF, 1.1 MB)
Poster clinical phase 2 data of MOR208 in combination with lenalidomide in CLL presented at the 2015 ASH Annual Meeting (Ohio State University)
(PDF, 1 MB)